Top

Published in:

Open Access 01-12-2011 | Research

miR-449 inhibits cell proliferation and is down-regulated in gastric cancer

Authors: Tony Bou Kheir, Ewa Futoma-Kazmierczak, Anders Jacobsen, Anders Krogh, Linda Bardram, Christoffer Hother, Kirsten Grønbæk, Birgitte Federspiel, Anders H Lund, Lennart Friis-Hansen

Published in: Molecular Cancer | Issue 1/2011

Abstract

Background

Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause of cancer related death. The development of gastric cancer is mainly associated with H. Pylori infection leading to a focus in pathology studies on bacterial and environmental factors, and to a lesser extent on the mechanistic development of the tumour. MicroRNAs are small non-coding RNA molecules involved in post-transcriptional gene regulation. They are found to regulate genes involved in diverse biological functions and alterations in microRNA expression have been linked to the pathogenesis of many malignancies. The current study is focused on identifying microRNAs involved in gastric carcinogenesis and to explore their mechanistic relevance by characterizing their targets.

Results

Invitrogen NCode miRNA microarrays identified miR-449 to be decreased in 1-year-old Gastrin KO mice and in H. Pylori infected gastric tissues compared to tissues from wild type animals. Growth rate of gastric cell lines over-expressing miR-449 was inhibited by 60% compared to controls. FACS cell cycle analysis of miR-449 over-expressing cells showed a significant increase in the sub-G₁ fraction indicative of apoptosis. ß-Gal assays indicated a senescent phenotype of gastric cell lines over-expressing miR-449. Affymetrix 133v2 arrays identified GMNN, MET, CCNE2, SIRT1 and CDK6 as miR-449 targets. Luciferase assays were used to confirm GMNN, MET, CCNE2 and SIRT1 as direct targets. We also show that miR-449 over-expression activated p53 and its downstream target p21 as well as the apoptosis markers cleaved CASP3 and PARP. Importantly, qPCR analyses showed a loss of miR-449 expression in human clinical gastric tumours compared to normal tissues.

Conclusions

In this study, we document a diminished expression of miR-449 in Gastrin KO mice and further confirmed its loss in human gastric tumours. We investigated the function of miR-449 by identifying its direct targets. Furthermore we show that miR-449 induces senescence and apoptosis by activating the p53 pathway.

Available only for authorised users

Smith MG, Hold GL, Tahara E, El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006, 12: 2979-2990.PubMedCentralPubMed

Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P: New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res. 2008, 146: 149-158. 10.1016/j.jss.2007.06.011CrossRefPubMed

Polk DB, Peek RM: Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010, 10: 403-414. 10.1038/nrc2857PubMedCentralCrossRefPubMed

Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000, 118: 36-47. 10.1016/S0016-5085(00)70412-4CrossRefPubMed

Takaishi S, Tu S, Dubeykovskaya ZA, Whary MT, Muthupalani S, Rickman BH, Rogers AB, Lertkowit N, Varro A, Fox JG, Wang TC: Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am J Pathol. 2009, 175: 365-375. 10.2353/ajpath.2009.081165PubMedCentralCrossRefPubMed

Zavros Y, Eaton KA, Kang W, Rathinavelu S, Katukuri V, Kao JY, Samuelson LC, Merchant JL: Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene. 2005, 24: 2354-2366. 10.1038/sj.onc.1208407CrossRefPubMed

Friis-Hansen L: Achlorhydria is associated with gastric microbial overgrowth and development of cancer: lessons learned from the gastrin knockout mouse. Scand J Clin Lab Invest. 2006, 66: 607-621. 10.1080/00365510600873894CrossRefPubMed

Elso CM, Lu X, Culiat CT, Rutledge JC, Cacheiro NL, Generoso WM, Stubbs LJ: Heightened susceptibility to chronic gastritis, hyperplasia and metaplasia in Kcnq1 mutant mice. Hum Mol Genet. 2004, 13: 2813-2821. 10.1093/hmg/ddh307CrossRefPubMed

Judd LM, Andringa A, Rubio CA, Spicer Z, Shull GE, Miller ML: Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(-/-)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors. J Gastroenterol Hepatol. 2005, 20: 1266-1278. 10.1111/j.1440-1746.2005.03867.xCrossRefPubMed

10.

Friis-Hansen L, Sundler F, Li Y, Gillespie PJ, Saunders TL, Greenson JK, Owyang C, Rehfeld JF, Samuelson LC: Impaired gastric acid secretion in gastrin-deficient mice. Am J Physiol. 1998, 274: G561-568.PubMed

11.

Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL: Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology. 2002, 122: 119-133. 10.1053/gast.2002.30298CrossRefPubMed

12.

Friis-Hansen L, Rieneck K, Nilsson HO, Wadstrom T, Rehfeld JF: Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology. 2006, 131: 246-258. 10.1053/j.gastro.2006.04.031CrossRefPubMed

13.

Kato M, Slack FJ: microRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell. 2008, 100: 71-81. 10.1042/BC20070078CrossRefPubMed

14.

Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010, 79: 351-379. 10.1146/annurev-biochem-060308-103103CrossRefPubMed

15.

Petri A, Lindow M, Kauppinen S: MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res. 2009, 69: 393-395. 10.1158/0008-5472.CAN-08-2749CrossRefPubMed

16.

Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-714. 10.1038/nrg2634PubMedCentralCrossRefPubMed

17.

Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005, 102: 3627-3632. 10.1073/pnas.0500613102PubMedCentralCrossRefPubMed

18.

Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007, 449: 682-688. 10.1038/nature06174CrossRefPubMed

19.

Medina PP, Nolde M, Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010, 467: 86-90. 10.1038/nature09284CrossRefPubMed

20.

Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T: Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009, 23: 2700-2704. 10.1101/gad.1848209PubMedCentralCrossRefPubMed

21.

Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96: 111-115. 10.1111/j.1349-7006.2005.00015.xCrossRefPubMed

22.

Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, Imai K, Shinomura Y, Tokino T, Baylin SB: A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res. 2008, 68: 2570-2575. 10.1158/0008-5472.CAN-07-6405PubMedCentralCrossRefPubMed

23.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008, 359: 2641-2650. 10.1056/NEJMoa0803785PubMedCentralCrossRefPubMed

24.

Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B: Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 2002, 36: 20-42. 10.1258/0023677021911740CrossRefPubMed

25.

Bjorkholm B, Lundin A, Sillen A, Guillemin K, Salama N, Rubio C, Gordon JI, Falk P, Engstrand L: Comparison of genetic divergence and fitness between two subclones of Helicobacter pylori. Infect Immun. 2001, 69: 7832-7838. 10.1128/IAI.69.12.7832-7838.2001PubMedCentralCrossRefPubMed

26.

Nilsson HO, Ouis IS, Stenram U, Ljungh A, Moran AP, Wadstrom T, Al-Soud WA: High prevalence of Helicobacter Species detected in laboratory mouse strains by multiplex PCR-denaturing gradient gel electrophoresis and pyrosequencing. J Clin Microbiol. 2004, 42: 3781-3788. 10.1128/JCM.42.8.3781-3788.2004PubMedCentralCrossRefPubMed

27.

Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80- 10.1186/gb-2004-5-10-r80PubMedCentralCrossRefPubMed

28.

Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010, 5: e8836- 10.1371/journal.pone.0008836PubMedCentralCrossRefPubMed

29.

Jacobsen A, Wen J, Marks DS, Krogh A: Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res. 2010, 20: 1010-1019. 10.1101/gr.103259.109PubMedCentralCrossRefPubMed

30.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007, 26: 731-743. 10.1016/j.molcel.2007.05.017CrossRefPubMed

31.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26: 745-752. 10.1016/j.molcel.2007.05.010PubMedCentralCrossRefPubMed

32.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D: A microRNA component of the p53 tumour suppressor network. Nature. 2007, 447: 1130-1134. 10.1038/nature05939PubMedCentralCrossRefPubMed

33.

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007, 6: 1586-1593. 10.4161/cc.6.13.4436CrossRefPubMed

34.

Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008, 105: 13421-13426. 10.1073/pnas.0801613105PubMedCentralCrossRefPubMed

35.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106CrossRefPubMed

36.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43CrossRefPubMed

37.

Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010, 8: 437-447.PubMed

38.

Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009, 126: 615-628. 10.1007/s00439-009-0722-xPubMedCentralCrossRefPubMed

39.

Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol. 1994, 144: 511-517.PubMedCentralPubMed

40.

Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA: CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis. 2002, 23: 419-424. 10.1093/carcin/23.3.419CrossRefPubMed

41.

Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W: Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells. Gastroenterology. 2010, 139: 1333-1343. 10.1053/j.gastro.2010.06.018PubMedCentralCrossRefPubMed

42.

Jiaqing L, Hokita S, Xiangming C, Natsugoe S, Tanabe G, Baba M, Takao S, Aikou T: Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer. 1998, 1: 160-165. 10.1007/s101200050011CrossRefPubMed

43.

Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?. Dig Dis Sci. 2009, 54: 1015-1020. 10.1007/s10620-008-0464-yCrossRefPubMed

44.

Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991, 325: 1127-1131. 10.1056/NEJM199110173251603CrossRefPubMed

45.

Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991, 325: 1132-1136. 10.1056/NEJM199110173251604CrossRefPubMed

46.

Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M: Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 2010, 70: 4719-4727. 10.1158/0008-5472.CAN-09-4620CrossRefPubMed

47.

Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z: Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010, 14: 1170-1179. 10.1007/s11605-010-1202-2CrossRefPubMed

48.

Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010, 6: e1000879- 10.1371/journal.pgen.1000879PubMedCentralCrossRefPubMed

49.

Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010, 70: 2339-2349. 10.1158/0008-5472.CAN-09-2777CrossRefPubMed

50.

Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H: Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010, 9: 16- 10.1186/1476-4598-9-16PubMedCentralCrossRefPubMed

51.

Kim MS, Oh JE, Kim YR, Park SW, Kang MR, Kim SS, Ahn CH, Yoo NJ, Lee SH: Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J Pathol. 2010, 221: 139-146. 10.1002/path.2683CrossRefPubMed

52.

Zhou H, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX: Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med. 2010, 88: 709-717. 10.1007/s00109-010-0617-2CrossRefPubMed

53.

Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11: 136-146. 10.1016/S1470-2045(09)70343-2PubMedCentralCrossRefPubMed

54.

Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010, 102: 1174-1179. 10.1038/sj.bjc.6605608PubMedCentralCrossRefPubMed

55.

Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009, 23: 2388-2393. 10.1101/gad.1819009PubMedCentralCrossRefPubMed

56.

Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009, 28: 1714-1724. 10.1038/onc.2009.19CrossRefPubMed

57.

Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009, 18: 50-55. 10.1097/CEJ.0b013e328305a07aCrossRefPubMed

58.

Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC: Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med. 2010, 8: 27- 10.1186/1479-5876-8-27PubMedCentralCrossRefPubMed

59.

Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini R, Isaia E, Sale P: Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 2009, 23: 3335-3346. 10.1096/fj.08-128579CrossRefPubMed

60.

Lize M, Pilarski S, Dobbelstein M: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2009, 17: 452-458. 10.1038/cdd.2009.188CrossRefPubMed

61.

Feng M, Yu Q: miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle. 2010, 9: 213-214. 10.4161/cc.9.2.10502CrossRefPubMed

62.

Welch C, Chen Y, Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007, 26: 5017-5022. 10.1038/sj.onc.1210293CrossRefPubMed

63.

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008, 7: 2591-2600. 10.4161/cc.7.16.6533CrossRefPubMed

64.

Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010, 17: 236-245. 10.1038/cdd.2009.109CrossRefPubMed

Title: miR-449 inhibits cell proliferation and is down-regulated in gastric cancer
Authors: Tony Bou Kheir
Ewa Futoma-Kazmierczak
Anders Jacobsen
Anders Krogh
Linda Bardram
Christoffer Hother
Kirsten Grønbæk
Birgitte Federspiel
Anders H Lund
Lennart Friis-Hansen
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2011
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-10-29

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Regulation of PBX3 expression by androgen and Let-7d in prostate cancer

Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR

Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma

L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer

Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer